Abera Bioscience AB (“Abera”) today announces positive results from a preclinical study conducted in collaboration with Orexo AB. The study explored the effect of Abera’s

Abera Bioscience has recently conducted a Scientific Advice meeting with the Swedish Medical Products Agency (MPA) regarding the company’s intranasal vaccine candidate against pneumococcal infections,

[English version further down] Uppdatering och fördjupning kring Aberas verksamhet  Det har hänt mycket i Abera Bioscience verksamhet senaste tiden med många positiva nyheter. Bolaget

Abera Bioscience AB (publ) meddelar idag att styrelseledamoten Sohila Zadran på egen begäran avgår från styrelsen av personliga skäl. ”Vi tackar Sohila för hennes hjälp

Sammanfattning av bokslutskommunikén: FINANSIELL ÖVERSIKT FJÄRDE KVARTALET 2024 Nettoomsättningen uppgick till 0 (0) kSEK. Övriga rörelseintäkter uppgick till 4 724 (2 600) kSEK Resultatet efter finansiella

Abera Bioscience (“Abera” or “the Company”) is a global leader in mucosal vaccine development, specializes in innovative vaccine candidates based on its proprietary platform technologies.

Abera Bioscience and Orexo AB are entering into a collaboration to develop and test Abera’s vaccine candidates in powder formulations. Abera develops mucosal vaccines based

Abera Bioscience (“Abera” or “the Company”) presents very promising results from a comparative study where their pneumococcal vaccine candidate, Ab-01.12, was compared to the world-leading

Abera Bioscience AB (“Abera” or “the company”) has received the final decision to approve its patent application “Display of heterologous molecules on bacterial cells and

FINANSIELL ÖVERSIKT TREDJE KVARTALET 2024 Nettoomsättningen uppgick till 0 (0) kSEK. Övriga rörelseintäkter uppgick till 3 348 (0) kSEK Resultatet efter finansiella poster uppgick till

Abera Bioscience (“Abera” or “the Company”), the world’s leading biotechnology company in mucosal vaccines, announces that it is starting in vivo studies for its new

OSLO/STOCKHOLM, 28 october 2024 Researchers at Abera Bioscience are set to test whether their bacterial-based platform could strengthen intranasal vaccines being developed to protect against

Abera Bioscience AB (“Abera” or “the Company”) has been awarded a 1 million SEK grant from Vinnova to advance the development of its innovative pneumococcal

Abera Bioscience AB (“Abera”) is advancing its vaccine candidates, utilizing its proprietary Outer Membrane Vesicles (OMVs) and Protein Bodies platforms. One indication in the growing

FINANSIELL ÖVERSIKT ANDRA KVARTALET 2024 Nettoomsättningen uppgick till 0 (0) kSEK. Övriga rörelseintäkter uppgick till 4 506 (44) kSEK Resultatet efter finansiella poster uppgick till

The Annual General Meeting 2024 of Abera Bioscience AB (“Abera” or the “Company”) was held on June 12, 2024 and made the following decisions: Approval

PhD Sohila Zadran is nominated as a new board member at the annual general meeting of Abera Bioscience AB (“Abera” or the “Company”). PhD Sohila

To the annual meeting of Abera Bioscience AB (“Abera” or “the Company”), Harry Råsted is nominated as a new board member. He possesses long experience

Sammanfattning av delårsrapporten FINANSIELL ÖVERSIKT FÖRSTA KVARTALET 2024 Nettoomsättningen uppgick till 0 (0) kSEK. Övriga rörelseintäkter uppgick till 2 270 (1) kSEK Resultatet efter finansiella

English version can be found below All documents related to the Annual meeting 2024 can be found here > Kallelse till årsstämma i Abera Bioscience

Abera Bioscience AB (publ) meddelar idag att bolaget publicerar årsredovisningen för 2023. Årsredovisning finns tillgänglig på bolagets hemsida under “Investors” samt via bifogad PDF: Annual

Abera Bioscience AB (“Abera” or “the company”) has received a preliminary approval notice for the company’s patent application “Display of heterologous molecules on bacterial cells

Abera Bioscience AB (“Abera” or “the Company”) recruits Ann-Christin Magnusson as the Lab Manager for the newly established lab in Uppsala. Ann-Christin brings extensive experience

Abera Bioscience AB (“Abera” or “the Company”) is taking a significant step in its development and will establish a new laboratory in Uppsala, Sweden, during

Sammanfattning av bokslutskommuniké för 2023. FINANSIELL ÖVERSIKT HELÅRET 2023 – KONCERNEN Nettoomsättningen uppgick till 0 (0) kSEK. Övriga rörelseintäkter uppgick till 2 646 (1 850) kSEK Resultatet

Abera Bioscience AB:s (”Abera” eller ”Bolaget”) har gjort flera viktiga framsteg med sin vaccinplattform för mukosala vacciner och har därför beslutat att utveckla en nasal vaccinkandidat mot

Abera Bioscience (“Abera” or “the Company”) has concluded the last toxicological study with Ab-01.12 and received the final report, demonstrating that the vaccine is well-tolerated,

Abera Bioscience AB (“Abera” or “the Company”) is actively advancing its vaccine candidates, leveraging proprietary vaccine platforms centered around Outer Membrane Vesicles (OMVs) and Protein

Sammanfattning av delårsrapporten FINANSIELL ÖVERSIKT TREDJE KVARTALET 2023 Nettoomsättningen uppgick till 0 (0) kSEK. Övriga rörelseintäkter uppgick till 0 (1 047) kSEK Resultatet efter finansiella

Abera Bioscience (“Abera”), a novel vaccine platform company specialized in mucosal vaccine development, is pleased to announce the receipt of a £ 1.8 million funding